MedTrace Logo

A Double-blind, Parallel Group, Comparative Study of Coadministration AD-4833 and SYR-322

NCT01686711 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 207

Last updated 2023-08-31

No results posted yet for this study

Summary

To evaluate the efficacy and safety of coadministration AD-4833 and SYR-322 in patients with diabetes mellitus.

Conditions

Interventions

DRUG

AD-4833 15 mg

DRUG

AD-4833 30 mg

DRUG

Placebo

Sponsors & Collaborators

Principal Investigators

  • Study Director · Takeda (Note: This product was divested to Teijin Pharma Limited in 2023)

Study Design

Purpose
TREATMENT
Model
PARALLEL

Eligibility

Min Age
20 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-09-30
Primary Completion
2013-12-31
Completion
2013-12-31

Countries

  • Japan

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01686711 on ClinicalTrials.gov